Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Hunter, David J ^a,b   Pike, Marilyn C ^c   Jonas, Beth L ^d   Kissin, Eugene ^e   Krop, Julie ^f   McAlindon, Tim ^g  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MedPharm Consulting Inc (For Stryker Biotech)   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f Stryker Orthopaedics   (United States)

^g TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBUPROFEN; PARACETAMOL; RECOMBINANT OSTEOGENIC PROTEIN 1; OSTEOGENIC PROTEIN 1;

ACUTE CHOLECYSTITIS; ADULT; ARTHRALGIA; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; JOINT STIFFNESS; JOINT SWELLING; KNEE OSTEOARTHRITIS; KNEE PAIN; LYMPHADENOPATHY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; AGED; KNEE; METABOLISM; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; BONE MORPHOGENETIC PROTEIN 7; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 77957576130     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-232     Document Type: Article

References (22)

1. Prevalence and impact of chronic joint symptoms - seven states, 1996. MMWR - Morbidity & Mortality Weekly Report 1998 47 345 351
2. Arthritis prevalence and activity limitations in older adults. DD Dunlop LM Manheim J Song RW Chang, Arthritis & Rheumatism 2001 44 212 221
3. Prevalence of disabilities and associated health conditions among adults - United States, 1999. [erratum appears in MMWR Morb Mortal Wkly Rep 2001 Mar 2;50(8):149.]. MMWR - Morbidity & Mortality Weekly Report 2001 50 120 125
4. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. AA Guccione DT Felson JJ Anderson JM Anthony Y Zhang PW Wilson, et al. American Journal of Public Health 1994 84 351 358 10.2105/AJPH.84.3.351 8129049
5. Management of common musculoskeletal problems: a survey of Ontario primary care physicians.[see comment]. RH Glazier DM Dalby EM Badley GA Hawker MJ Bell R Buchbinder, et al. CMAJ Canadian Medical Association Journal 1998 158 1037 1040
6. [Targeted anti-cytokine therapies for osteoarthritis]. [Review] [26 refs] [French]. X Chevalier B Mugnier G Bouvenot X Chevalier B Mugnier G Bouvenot, Bulletin de l Academie Nationale de Medecine 2006 190 1411 1420 17450677
7. Effect of polymerized-type I collagen in knee osteoarthritis. II. In vivo study. J Furuzawa-Carballeda OA Munoz-Chable SI Macias-Hernandez A Agualimpia-Janning, Eur J Clin Invest 2009 39 598 606 10.1111/j.1365-2362.2009. 02144.x 19397687
8. Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro study. J Furuzawa-Carballeda OA Munoz-Chable J Barrios-Payan R Hernandez-Pando, Eur J Clin Invest 2009 39 591 597 10.1111/j.1365-2362.2009.02154.x 19453649
9. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. DL Griffith PC Keck TK Sampath DC Rueger WD Carlson, Proc Natl Acad Sci USA 1996 93 878 883 10.1073/pnas.93.2.878 8570652
10. The TGF-beta family and its composite receptors. J Massague L Attisano JL Wrana, Trends Cell Biol 1994 4 172 178 10.1016/0962-8924(94)90202-X 14731645
11. Recent advances in BMP receptor signaling. C Sieber J Kopf C Hiepen P Knaus, Cytokine Growth Factor Rev 2009 20 343 355 10.1016/j.cytogfr.2009.10.007 19897402
12. Overview of bone morphogenetic proteins. JM Wozney, Spine (Phila Pa 1976 ) 2002 27 2 S8 12205411
13. Osteogenic protein-1: biology and applications. SD Cook DC Rueger, Clin Orthop Relat Res 1996 29 38 10.1097/00003086-199603000-00005 8595770
14. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage. C Merrihew B Kumar K Heretis DC Rueger KE Kuettner S Chubinskaya, J Orthop Res 2003 21 899 907 10.1016/S0736-0266(03)00055-X 12919879 (Pubitemid 37045569)
15. Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Y Nishida CB Knudson W Knudson, Osteoarthritis Cartilage 2004 12 374 382 10.1016/j.joca.2004.01.008 15094136
16. Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. M Jelic M Pecina M Haspl J Kos K Taylor D Maticic, et al. Growth Factors 2001 19 101 113 10.3109/08977190109001079 11769970
17. Repair of articular cartilage defects with osteogenic protein-1 (BMP-7) in dogs. SD Cook LP Patron SL Salkeld DC Rueger, J Bone Joint Surg Am 2003 85-A Suppl 3 116 123 12925618
18. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. RS Sellers D Peluso EA Morris, J Bone Joint Surg Am 1997 79 1452 1463 9378731
19. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. N Bellamy WW Buchanan CH Goldsmith J Campbell LW Stitt, Journal of Rheumatology 1988 15 1833 1840 3068365
20. Knee Injury and Osteoarthritis Outcome Score (KOOS) - development of a self-administered outcome measure. EM Roos HP Roos LS Lohmander C Ekdahl BD Beynnon, Journal of Orthopaedic & Sports Physical Therapy 1998 28 88 96 (Pubitemid 28366508)
21. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. JEJ Ware CD Sherbourne, Medical Care 1992 30 473 483 10.1097/00005650-199206000-00002 1593914
22. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. T Pham HD van der RD Altman JJ Anderson N Bellamy M Hochberg, et al. Osteoarthritis & Cartilage 2004 12 389 399